Staphylococcal scalded skin syndrome

Staphylococcal scalded skin syndrome
Classification and external resources
Specialty
ICD-10	L00
ICD-9-CM	695.81
DiseasesDB	29437
MedlinePlus	001352
eMedicine	derm/402 emerg/782
Patient UK	Staphylococcal scalded skin syndrome
MeSH	D013206

Staphylococcal scalded skin syndrome, (SSSS), also known as Pemphigus neonatorum or Ritter's disease, or Localized bullous impetigo is a dermatological condition caused by Staphylococcus aureus.

Pathophysiology

The syndrome is induced by epidermolytic exotoxins (exfoliatin) A and B, which are released by S. aureus and cause detachment within the epidermal layer; by breaking down the desmosomes. One of the exotoxins is encoded on the bacterial chromosome, while the other is encoded on a plasmid. These exotoxins are proteases that cleave desmoglein-1, which normally holds the granulosum and spinosum layers together.

Signs and symptoms

The disease presents with the widespread formation of fluid-filled blisters that are thin walled and easily ruptured and the patient can be positive for Nikolsky's sign. Ritter's Disease of the Newborn is the most severe form of SSSS with similar signs and symptoms. SSSS often includes a widespread painful erythroderma, often involving the face, diaper, and other intertriginous areas. Extensive areas of desquamation might be present. Perioral crusting and fissuring are seen early in the course. Unlike toxic epidermal necrolysis, SSSS spares the mucous membranes. It is most common in children under 6 years, but can be seen in adults who are immunosuppressed or have renal failure.

Diagnosis

The diagnosis of SSSS is made clinically. This is sometimes confirmed by isolation of S. aureus from blood, mucous membranes, or skin biopsy; however, these are often negative. Skin biopsy may show separation of the superficial layer of the epidermis (intraepidermal separation), differentiating SSSS from TEN, wherein the separation occurs at the dermo-epidermal junction (subepidermal separation). SSSS may be difficult to distinguish from toxic epidermal necrolysis and pustular psoriasis.

Treatment

The mainstay of treatment for SSSS is supportive care along with eradication of the primary infection. Conservative measures include rehydration, antipyretics, management of thermal burns, and stabilization. Parenteral antibiotics to cover S. aureus should be administered. Most strains of S. aureus implicated in SSSS have penicillinases, and are therefore penicillin resistant. Therefore, treatment with Nafcillin, oxacillin, or vancomycin is typically indicated. Clindamycin is sometimes also used because of its inhibition of exotoxins.

Prognosis

The prognosis of SSSS in children is excellent, with complete resolution within 10 days of treatment, and without significant scarring. However, SSSS must be differentiated carefully from toxic epidermal necrolysis, which carries a poor prognosis. The prognosis in adults is generally much worse, and depends upon various factors such as time to treatment, host immunity, and comorbidities.

History

The clinical features were first described in 1878 by Baron Gottfried Ritter von Rittershain, who observed 297 cases among children in a single Czechoslovakian children's home over a 10-year period.

In 1885 Nil Filatow and in 1894 Clement Dukes described an exantematous disease which they thought to be a form of rubella, but in 1900 Dukes identified it to be a separate entity which came to be known by the names Dukes' disease, Filatov’s disease or fourth disease. Although Dukes identified it as a separate entity, it is thought not to be different from scarlet fever caused by Staphylococcal exotoxin after Keith Powell proposed equating it with the condition currently known as Staphylococcal scalded skin syndrome in 1979.

See also

• Dukes' disease
• List of cutaneous conditions
• List of conditions caused by problems with junctional proteins